Solid Tumors | Norton Healthcare

Indication: Solid Tumors

PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Pfizer

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.